降脂通脉汤内服联合大黄敷脐治疗冠心病伴高血脂症疗效及对血清Hcy、IL-6、APN和血脂指标的影响
|
摘要
目的观察降脂通脉汤内服联合大黄敷脐治疗冠心病伴高血脂症疗效及对血清同型半胱氨酸(Hcy)、白细胞介素-6(IL-6)、脂联素(APN)水平和血脂指标的影响。方法将110例冠心病伴高血脂症患者随机分为研究组和对照组各55例,2组均给予常规西药治疗,在此基础上对照组给予大黄敷脐治疗,研究组在对照组治疗基础上联合降脂通脉汤治疗,均治疗4周。观察2组治疗前后中医证候积分、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)和血清Hcy、IL-6、APN水平变化情况,统计2组临床疗效。结果治疗后2组中医证候积分和TG、TC、LDL-C、Hcy、IL-6水平均显著低于治疗前(P均<0.05),且研究组显著低于对照组(P均<0.05);2组HDL-C、APN水平均显著高于治疗前(P均<0.05),且研究组显著高于对照组(P均<0.05)。研究组总有效率显著高于对照组(P<0.05)。结论降脂通脉汤内服联合大黄敷脐可有效调节冠心病伴高血脂症患者血脂水平和血清Hcy、IL-6、APN水平,提高临床疗效。
Objective It is to observe the curative effect of Jiangzhi Tongmai Decoction combined with umbilical compress therapy with Dahuang on coronary heart disease with hyperlipidemia and its effect on serum homocysteine(Hcy), interleukin-6(IL-6), adiponectin(APN) and blood lipids. Methods 110 patients with coronary heart disease and hyperlipidemia were randomly divided into study group and control group, 55 cases in each group. Both groups were treated with conventional western medicine. On the basis of this, the control group was treated with umbilical compress therapy with Dahuang, and the study group was treated with Jiangzhi Tongmai Decoction. Both groups were treated for 4 weeks. The clinical efficacy was assessed after 4 weeks of treatment. The changes of TCM syndrome scores, the levels of triglyceride(TG), total cholesterol(TC), high density lipoprotein(HLD-C), and low density lipoprotein(LDL-C) and serum levels of Hcy, IL-6, and APN were observed before and after treatment in the two groups. Results The scores of TCM syndrome and the levels of TG, TC, LDL-C, Hcy and IL-6 after treatment in the two groups were significantly lower than those before treatment(P<0.05), the scores and levels in the study group were significantly lower than those in the control group(P<0.05); the levels of HLD-C and APN in the two groups were significantly higher than those before treatment(P<0.05), and that in the study group was significantly higher than the control group(P<0.05). The total effective rate of the study group was significantly higher than that of the control group(P<0.05). Conclusion Jiangzhi Tongmai Decoction combined with umbilical compress therapy with Dahuang can effectively regulate blood lipid levels and serum levels of Hcy, IL-6 and APN and improve clinical efficacy in patients with coronary heart disease and hyperlipidemia.
Objective It is to observe the curative effect of Jiangzhi Tongmai Decoction combined with umbilical compress therapy with Dahuang on coronary heart disease with hyperlipidemia and its effect on serum homocysteine(Hcy), interleukin-6(IL-6), adiponectin(APN) and blood lipids. Methods 110 patients with coronary heart disease and hyperlipidemia were randomly divided into study group and control group, 55 cases in each group. Both groups were treated with conventional western medicine. On the basis of this, the control group was treated with umbilical compress therapy with Dahuang, and the study group was treated with Jiangzhi Tongmai Decoction. Both groups were treated for 4 weeks. The clinical efficacy was assessed after 4 weeks of treatment. The changes of TCM syndrome scores, the levels of triglyceride(TG), total cholesterol(TC), high density lipoprotein(HLD-C), and low density lipoprotein(LDL-C) and serum levels of Hcy, IL-6, and APN were observed before and after treatment in the two groups. Results The scores of TCM syndrome and the levels of TG, TC, LDL-C, Hcy and IL-6 after treatment in the two groups were significantly lower than those before treatment(P<0.05), the scores and levels in the study group were significantly lower than those in the control group(P<0.05); the levels of HLD-C and APN in the two groups were significantly higher than those before treatment(P<0.05), and that in the study group was significantly higher than the control group(P<0.05). The total effective rate of the study group was significantly higher than that of the control group(P<0.05). Conclusion Jiangzhi Tongmai Decoction combined with umbilical compress therapy with Dahuang can effectively regulate blood lipid levels and serum levels of Hcy, IL-6 and APN and improve clinical efficacy in patients with coronary heart disease and hyperlipidemia.
引文
[1] 郭晓阳.降脂化瘀方治疗痰瘀互结型高脂血症临床观察[J].四川中医,2015,33(7):135-136
[2] 王肃馨,张治祥.降脂通脉汤联合阿托伐他汀钙片治疗冠心病合并高脂血症疗效观察[J].实用中医药杂志,2016,32(9):889-890
[3] 尤秀梅.降脂通脉胶囊联合阿托伐他汀治疗高脂血症60例[J].河南中医,2015,35(12):3104-3106
[4] 张莹.降脂通脉饮联合辛伐他汀治疗高脂血症随机平行对照研究[J].实用中医内科杂志,2016,30(2):59-61
[5] 颜红兵.临床冠心病诊断与治疗指南[M].北京:人民卫生出版社,2010:203-204
[6] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中国实用乡村医生杂志,2012,19(16):390-419
[7] 国家中医药管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:228-229
[8] 国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1994
[9] 张太.理气活血化浊汤治疗气血瘀滞型高脂血症临床研究[J].中医学报,2012,27(4):481-482
[10] 王冬梅,李嵩岩,李良.通脉调脂方联合瑞舒伐他汀治疗冠心病并高脂血症的临床疗效及其对血清炎性因子水平的影响[J].实用心脑肺血管病杂志,2016,24(9):84-87
[11] 冀元元,李纲,刘志远,等.阿托伐他汀对冠心病炎症因子hs-CRP、TNF-α和IL-6水平的干预作用[J].中国生化药物杂志,2014,34(7):147-149
[12] 廖雪梅,王洪宇,钟伟,等.老年冠心病与脂联素及N端脑钠肽前体水平的相关性研究[J].重庆医学,2016,45(17):2355-2356
[13] 朱敏.大黄敷脐治疗痰浊瘀阻型高脂血症的临床研究[D].广州:广州中医药大学,2013
[14] 邓俊,张贵,张元爱,等.补阳还五汤口服联合大黄敷脐治疗冠心病心绞痛伴高脂血症临床观察[J].中国中医药信息杂志,2012,19(8):67-68
[15] 陈立生.降脂汤治疗冠心病(痰浊血瘀证)合并高脂血症的临床观察[J].泸州医学院学报,2015,38(3):286-288
[2] 王肃馨,张治祥.降脂通脉汤联合阿托伐他汀钙片治疗冠心病合并高脂血症疗效观察[J].实用中医药杂志,2016,32(9):889-890
[3] 尤秀梅.降脂通脉胶囊联合阿托伐他汀治疗高脂血症60例[J].河南中医,2015,35(12):3104-3106
[4] 张莹.降脂通脉饮联合辛伐他汀治疗高脂血症随机平行对照研究[J].实用中医内科杂志,2016,30(2):59-61
[5] 颜红兵.临床冠心病诊断与治疗指南[M].北京:人民卫生出版社,2010:203-204
[6] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中国实用乡村医生杂志,2012,19(16):390-419
[7] 国家中医药管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:228-229
[8] 国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1994
[9] 张太.理气活血化浊汤治疗气血瘀滞型高脂血症临床研究[J].中医学报,2012,27(4):481-482
[10] 王冬梅,李嵩岩,李良.通脉调脂方联合瑞舒伐他汀治疗冠心病并高脂血症的临床疗效及其对血清炎性因子水平的影响[J].实用心脑肺血管病杂志,2016,24(9):84-87
[11] 冀元元,李纲,刘志远,等.阿托伐他汀对冠心病炎症因子hs-CRP、TNF-α和IL-6水平的干预作用[J].中国生化药物杂志,2014,34(7):147-149
[12] 廖雪梅,王洪宇,钟伟,等.老年冠心病与脂联素及N端脑钠肽前体水平的相关性研究[J].重庆医学,2016,45(17):2355-2356
[13] 朱敏.大黄敷脐治疗痰浊瘀阻型高脂血症的临床研究[D].广州:广州中医药大学,2013
[14] 邓俊,张贵,张元爱,等.补阳还五汤口服联合大黄敷脐治疗冠心病心绞痛伴高脂血症临床观察[J].中国中医药信息杂志,2012,19(8):67-68
[15] 陈立生.降脂汤治疗冠心病(痰浊血瘀证)合并高脂血症的临床观察[J].泸州医学院学报,2015,38(3):286-288